|
Valoración DCF de Ligand Pharmaceuticals Incorporated (LGND)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Ligand Pharmaceuticals Incorporated (LGND) Bundle
¡Mejore sus opciones de inversión con la calculadora DCF (LGND)! Utilice datos financieros de productos farmacéuticos de ligando reales, ajuste las proyecciones y gastos de crecimiento, y observe instantáneamente cómo estas modificaciones influyen en el valor intrínseco de (LGND).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.3 | 186.4 | 277.1 | 196.2 | 131.3 | 144.9 | 159.9 | 176.4 | 194.7 | 214.8 |
| Revenue Growth, % | 0 | 54.98 | 48.66 | -29.19 | -33.09 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| EBITDA | 38.0 | 69.1 | 133.2 | 54.4 | 101.7 | 64.3 | 71.0 | 78.3 | 86.4 | 95.3 |
| EBITDA, % | 31.6 | 37.04 | 48.05 | 27.72 | 77.47 | 44.38 | 44.38 | 44.38 | 44.38 | 44.38 |
| Depreciation | 43.7 | 28.0 | 41.3 | 43.4 | 37.4 | 33.9 | 37.4 | 41.2 | 45.5 | 50.2 |
| Depreciation, % | 36.36 | 15 | 14.92 | 22.11 | 28.49 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 |
| EBIT | -5.7 | 41.1 | 91.8 | 11.0 | 64.3 | 30.4 | 33.6 | 37.1 | 40.9 | 45.1 |
| EBIT, % | -4.76 | 22.04 | 33.13 | 5.61 | 48.98 | 21 | 21 | 21 | 21 | 21 |
| Total Cash | 1,069.9 | 411.2 | 341.1 | 211.9 | 170.3 | 144.9 | 159.9 | 176.4 | 194.7 | 214.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 41.7 | 59.1 | 91.6 | 35.0 | 39.3 | 42.7 | 47.1 | 52.0 | 57.3 | 63.3 |
| Account Receivables, % | 34.71 | 31.68 | 33.07 | 17.85 | 29.94 | 29.45 | 29.45 | 29.45 | 29.45 | 29.45 |
| Inventories | 7.3 | 26.5 | 27.3 | 13.3 | 24.0 | 16.0 | 17.6 | 19.5 | 21.5 | 23.7 |
| Inventories, % | 6.07 | 14.21 | 9.86 | 6.77 | 18.25 | 11.03 | 11.03 | 11.03 | 11.03 | 11.03 |
| Accounts Payable | 2.4 | 3.8 | 8.4 | 5.3 | 2.4 | 3.4 | 3.7 | 4.1 | 4.5 | 5.0 |
| Accounts Payable, % | 2.01 | 2.03 | 3.03 | 2.7 | 1.85 | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
| Capital Expenditure | -2.6 | -4.5 | -8.8 | -17.9 | -3.5 | -5.6 | -6.2 | -6.9 | -7.6 | -8.4 |
| Capital Expenditure, % | -2.12 | -2.39 | -3.16 | -9.13 | -2.68 | -3.9 | -3.9 | -3.9 | -3.9 | -3.9 |
| Tax Rate, % | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 |
| EBITAT | -4.5 | 11.6 | 110.9 | -1.6 | 52.7 | 17.6 | 19.4 | 21.4 | 23.7 | 26.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.0 | .0 | 114.7 | 91.4 | 68.8 | 51.4 | 44.8 | 49.5 | 54.6 | 60.3 |
| WACC, % | 8.68 | 8.66 | 8.69 | 8.65 | 8.68 | 8.67 | 8.67 | 8.67 | 8.67 | 8.67 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 202.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 61 | |||||||||
| Terminal Value | 921 | |||||||||
| Present Terminal Value | 608 | |||||||||
| Enterprise Value | 811 | |||||||||
| Net Debt | -17 | |||||||||
| Equity Value | 827 | |||||||||
| Diluted Shares Outstanding, MM | 18 | |||||||||
| Equity Value Per Share | 46.59 |
What You Will Receive
- Comprehensive Financial Model: Utilize Ligand Pharmaceuticals' (LGND) actual data for an accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other crucial parameters.
- Real-Time Calculations: Automatic updates provide immediate insights as you adjust inputs.
- Professional-Grade Template: An expertly crafted Excel file tailored for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, allowing for repeated application in detailed forecasting.
Key Features
- 🔍 Real-Life LGND Financials: Pre-filled historical and projected data for Ligand Pharmaceuticals Incorporated.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Ligand’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Ligand’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Ligand Pharmaceuticals Incorporated’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment strategies.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by researchers, investors, and financial analysts.
- Comprehensive Data: Ligand Pharmaceuticals' (LGND) historical and projected financials included for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the entire process.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing portfolios focused on Ligand Pharmaceuticals (LGND).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Ligand Pharmaceuticals (LGND).
- Students and Educators: Utilize real-world data to learn and teach financial modeling techniques related to the biotech sector.
- Biotech Enthusiasts: Gain insights into how companies like Ligand Pharmaceuticals (LGND) are valued in the investment landscape.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Ligand Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Ligand Pharmaceuticals (LGND).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.